keyword
https://read.qxmd.com/read/38648056/prevalence-of-homologous-recombination-deficiency-among-patients-with-germline-rad51c-d-breast-or-ovarian-cancer
#1
JOURNAL ARTICLE
Sara Torres-Esquius, Alba Llop-Guevara, Sara Gutiérrez-Enríquez, Marcel Romey, Àlex Teulé, Gemma Llort, Ana Herrero, Pilar Sánchez-Henarejos, Anna Vallmajó, Santiago González-Santiago, Isabel Chirivella, Juana Maria Cano, Begoña Graña, Sara Simonetti, Isabela Díaz de Corcuera, Teresa Ramon Y Cajal, Judit Sanz, Sara Serrano, Andrea Otero, Cristina Churruca, Ana Beatriz Sánchez-Heras, Sonia Servitja, Carmen Guillén-Ponce, Joan Brunet, Carsten Denkert, Violeta Serra, Judith Balmaña
IMPORTANCE: RAD51C and RAD51D are involved in DNA repair by homologous recombination. Germline pathogenic variants (PVs) in these genes are associated with an increased risk of ovarian and breast cancer. Understanding the homologous recombination deficiency (HRD) status of tumors from patients with germline PVs in RAD51C/D could guide therapeutic decision-making and improve survival. OBJECTIVE: To characterize the clinical and tumor characteristics of germline RAD51C/D PV carriers, including the evaluation of HRD status...
April 1, 2024: JAMA Network Open
https://read.qxmd.com/read/38648017/an-innovative-breast-cancer-detection-framework-using-multiscale-dilated-densenet-with-attention-mechanism
#2
JOURNAL ARTICLE
Subhashini Ramachandran, Rajasekar Velusamy, Namakkal Venkataraman Srinivasan Sree Rathna Lakshmi, Chakaravarthi Sivanandam
Cancer-related deadly diseases affect both developed and underdeveloped nations worldwide. Effective network learning is crucial to more reliably identify and categorize breast carcinoma in vast and unbalanced image datasets. The absence of early cancer symptoms makes the early identification process challenging. Therefore, from the perspectives of diagnosis, prevention, and therapy, cancer continues to be among the healthcare concerns that numerous researchers work to advance. It is highly essential to design an innovative breast cancer detection model by considering the complications presented in the classical techniques...
April 22, 2024: Network: Computation in Neural Systems
https://read.qxmd.com/read/38647974/economic-assessment-of-abemaciclib-for-the-adjuvant-treatment-of-luminal-her2-breast-cancer-from-the-perspective-of-the-spanish-health-system
#3
JOURNAL ARTICLE
Silvia Fenix-Caballero, Adrián Sanchez-Vegas, Emilio Jesús Alegre Del-Rey, David Epstein, Leticia Garcia-Mochon, Antonio Olry de Labry Lima
INTRODUCTION: Abemaciclib is an oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Data from the clinical trial monarchE (2023) showed improved survival from invasive disease. The aim of the present article was to conduct an economic assessment of adjuvant treatment with abemaciclib in women with luminal, HER2- and node-positive breast cancer. METHODS: A Markov model was constructed with four mutually exclusive health states (disease-free, local recurrence, distal recurrence and death)...
April 22, 2024: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://read.qxmd.com/read/38647959/co-ii-coordination-complex-fluorescence-performances-and-combined-with-taxotere-hydrogels-on-breast-cancer-treatment-and-clinical-care
#4
JOURNAL ARTICLE
Hao Liu, Chengyi Wu, Haiying Yu
In this study, a novel coordination polymer {Co2 (Oaobtc)(bpe)(H2 O)4 ]}n (1) was synthesized under hydrothermal conditions using a hybrid ligand synthesis method, where H4Oobtc represents 2,3,3'-tricarboxylate azobenzene, and bpe represents 1,2-bis(4-pyridyl)ethylene. The obtained CP1 was characterized by elemental analysis (EA), powder X-ray diffraction (PXRD), and thermal gravimetric analysis (TGA). Fluorescence testing confirmed the excellent photoluminescent performance of compound 1, indicating its potential as a cyan-emitting fluorescent material...
April 22, 2024: Journal of Fluorescence
https://read.qxmd.com/read/38647915/the-role-of-axillary-lymph-node-dissection-versus-sentinel-lymph-node-dissection-in-breast-cancer-patients-with-clinical-n2b-n3c-disease-who-receive-adjuvant-radiotherapy
#5
JOURNAL ARTICLE
Eric A Roach, Christopher R Weil, George Cannon, Jon Grant, Margaret Van Meter, Dustin Boothe
BACKGROUND: For breast cancer with advanced regional lymph node involvement, axillary lymph node dissection (ALND) remains the standard of care for staging and treating the axilla despite the presence of undissected lymph nodes. The benefit of ALND in this setting is unknown. OBJECTIVES: We sought to describe national patterns of care of axillary surgery and its association with overall survival (OS) among women with cN2b-N3c breast cancer who receive adjuvant radiotherapy...
April 22, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38647846/cytotoxicity-of-subcritical-water-extracts-obtained-from-byproducts-generated-at-commercial-pecan-shelling-operations-on-cancer-cells
#6
JOURNAL ARTICLE
Canan Sevimli Gur, Nurhan Turgut Dunford, Zinar Pinar Gumus
This study examined potential of the extracts obtained from the byproducts generated at commercial pecan nut-shelling operations in cancer treatment. The subcritical water extracts obtained from two varieties, Native and Pawnee, were analyzed for their phenolic contents and compositions. Effects of the extracts on viability and IC50 of the human cell lines representing a broad range of cancer types, cervical, lung, skin, breast, colon and prostate cancers, were investigated. Although the effect of the temperature on the phenolic contents and compositions of the extracts was not statistically significant, the influence of the variety was extensive...
July 28, 2023: Bioresources and Bioprocessing
https://read.qxmd.com/read/38647725/the-ras-related-protein-rab22a-interacts-with-hypoxia-inducible-factor-1-alpha-hif-1%C3%AE-in-mda-mb-231-breast-cancer-cells-in-hypoxia
#7
JOURNAL ARTICLE
Nikolaos A Papanikolaou, Maria Kakavoulia, Christos Ladias, Athanasios G Papavassiliou
BACKGROUND: Recent studies suggest that hypoxia-inducible factor 1-alpha (HIF-1α) and the small GTPase protein Ras-related protein Rab-22 A (RAB22A) may be colocalized in the cytoplasm and that as a conequence they may enhance the formation of microvesicles in breast cancer cells under hypoxia. Therefore, we sought to determine whether these two proteins are present in intracellular complexes in breast carcinoma cells. METHODS AND RESULTS: Evaluation using molecular docking indicated that HIF-1α and RAB22A interact with each other...
April 22, 2024: Molecular Biology Reports
https://read.qxmd.com/read/38647591/social-characteristics-and-social-benefit-use-among-premenopausal-breast-cancer-survivors-in-denmark-a-population-based-cohort-study
#8
JOURNAL ARTICLE
Cathrine F Hjorth, Julie A Schmidt, Dóra K Farkas, Deirdre Cronin-Fenton
PURPOSE: In 2020, one million women aged < 55 years were diagnosed with breast cancer globally. The impact of breast cancer and its treatments on these women's ability to work and need for social benefits may differ by social characteristics. We evaluated social benefit use following breast cancer by education and cohabitation. METHODS: We conducted a nationwide population-based cohort study, including women aged 18-55 years diagnosed with stage I-III breast cancer in Denmark during 2002-2011...
April 22, 2024: Journal of Cancer Survivorship: Research and Practice
https://read.qxmd.com/read/38647447/fear-of-cancer-recurrence-in-breast-cancer-a-moderated-serial-mediation-analysis-of-a-prospective-international-study
#9
JOURNAL ARTICLE
Gabriella Bentley, Osnat Zamir, Ilan Roziner, Rawan Dahabre, Shlomit Perry, Evangelos C Karademas, Paula Poikonen-Saksela, Ketti Mazzocco, Albino J Oliveira-Maia, Ruth Pat-Horenczyk
OBJECTIVE: Women dealing with breast cancer (BC) face many challenges, one of which is the fear of cancer recurrence (FCR). This study examined whether disease severity predicts FCR 6 months after cancer diagnosis through psychological distress and whether cognitive-emotion regulation moderates this effect. METHOD: The study sample included 656 women from Italy (27.5%), Finland (31.9%), Israel (19.8%), and Portugal (20.8%) diagnosed with Stages I-III of BC. Participants' age ranged between 40 and 70 years ( M = 54...
April 22, 2024: Health Psychology: Official Journal of the Division of Health Psychology, American Psychological Association
https://read.qxmd.com/read/38647255/trps1-is-a-highly-sensitive-marker-for-breast-cancer-a-tissue-microarray-study-evaluating-more-than-19-000-tumors-from-152-different-tumor-entities
#10
JOURNAL ARTICLE
Maximilian Lennartz, Neele Löhr, Doris Höflmayer, Sebastian Dwertmann Rico, Clara von Bargen, Simon Kind, Viktor Reiswich, Florian Viehweger, Florian Lutz, Veit Bertram, Christoph Fraune, Natalia Gorbokon, Sören Weidemann, Niclas C Blessin, Claudia Hube-Magg, Anne Menz, Ria Schlichter, Till Krech, Andrea Hinsch, Eike Burandt, Guido Sauter, Ronald Simon, Martina Kluth, Andreas H Marx, Patrick Lebok, David Dum, Sarah Minner, Frank Jacobsen, Till S Clauditz, Christian Bernreuther, Stefan Steurer
Trichorhinophalangeal syndrome 1 (TRPS1) is a nuclear protein highly expressed in breast epithelial cells. TRPS1 immunohistochemistry (IHC) has been suggested as a breast cancer marker. To determine the diagnostic and prognostic utility of TRPS1 IHC, tissue microarrays containing 19,201 samples from 152 different tumor types and subtypes were analyzed. GATA3 IHC was performed in a previous study. TRPS1 staining was seen in 86 of 152 tumor categories with 36 containing at least one strongly positive case. TRPS1 staining predominated in various types of breast carcinomas (51%-100%), soft tissue tumors (up to 100%), salivary gland tumors (up to 46%), squamous cell carcinomas (up to 35%), and gynecological cancers (up to 40%)...
April 22, 2024: American Journal of Surgical Pathology
https://read.qxmd.com/read/38647165/cost-of-disease-progression-among-us-patients-with-human-epidermal-growth-factor-receptor-2-positive-metastatic-breast-cancer
#11
JOURNAL ARTICLE
Clara Lam, Brandon Diessner, Katherine Andrade, Sydnie Stackland, Leah Park, Sandhya Mehta, Feng Lin, Winghan Jackie Kwong
Aim: The objectives were to investigate the differences in per patient per month (PPPM) healthcare resource utilization (HCRU) and costs among commercially insured and Medicare Advantage patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (mBC) who experience disease progression in 12 months compared with those who don't investigate the impact of progression timing on cumulative healthcare costs. Patients & methods: This claims-based study included patients diagnosed with mBC between 1 January 2013 and 30 April 2020 and received HER2-targeted therapy...
April 22, 2024: Journal of Comparative Effectiveness Research
https://read.qxmd.com/read/38647142/demonstration-study-of-reflector-based-volumetric-speed-of-sound-imaging-with-linear-ultrasound-arrays
#12
JOURNAL ARTICLE
Xiaoyi Jiang, Kexin Gan, Yuxin Wang, Chao Tao, Xiaojun Liu, Jie Yuan, Zhibin Jin
Conventional B-mode ultrasound imaging has difficulty in delineating homogeneous soft tissues with similar acoustic impedances, as the reflectivity depends on the acoustic impedance at the interface. As a quantitative imaging biomarker sensitive to alteration of biomechanical properties, speed-of-sound (SoS) holds promising potential for tissue and disease differentiation such as delineation of different breast tissue types with similar acoustic impedance. Compared to two-dimensional (2D) SoS images, three-dimensional (3D) volumetric SoS images achieved through a full-angle ultrasound scan can reveal more intricate morphological structures of tissues; however, they generally require a ring transducer...
April 22, 2024: Ultrasonic Imaging
https://read.qxmd.com/read/38647072/comprehensive-profiling-of-l1-retrotransposons-in-mouse
#13
JOURNAL ARTICLE
Xuanming Zhang, Ivana Celic, Hannah Mitchell, Sam Stuckert, Lalitha Vedula, Jeffrey S Han
L1 elements are retrotransposons currently active in mammals. Although L1s are typically silenced in most normal tissues, elevated L1 expression is associated with a variety of conditions, including cancer, aging, infertility and neurological disease. These associations have raised interest in the mapping of human endogenous de novo L1 insertions, and a variety of methods have been developed for this purpose. Adapting these methods to mouse genomes would allow us to monitor endogenous in vivo L1 activity in controlled, experimental conditions using mouse disease models...
April 22, 2024: Nucleic Acids Research
https://read.qxmd.com/read/38646849/network-pharmacology-and-molecular-docking-based-strategy-for-predicting-anti-tumour-mechanism-of-linarin
#14
JOURNAL ARTICLE
Jun Wang, Jingjing Cheng
The aim was to explore the anti-tumour mechanism of linarin (LIN) based on network pharmacology and molecular docking. PharmMapper database and GeneCards database were used to screen anti-tumour related targets of LIN. Enrichment analysis of GO and KEGG was conducted to predict the key targets and pathways. At last, LIN was docked with the key targets. ESR1, ESR2, EGFR, AR, TGFBR2, F2, MAPK10, MAPK14, CDK2 and HSP90AA1 were identified as the key targets. The key pathways included pathways in cancer, prostate cancer, pancreatic cancer and breast cancer...
April 22, 2024: Natural Product Research
https://read.qxmd.com/read/38646723/-68-ga-labeled-epha2-targeted-cyclic-peptide-a-novel-positron-imaging-tracer-for-triple-negative-breast-cancer
#15
JOURNAL ARTICLE
Bin Qu, Xianjun Li, Yuze Ma, Yanzhi Wang, Yeming Han, Guihua Hou, Feng Gao
The absence of better biomarkers currently limits early diagnosis and treatment of triple-negative breast cancer (TNBC). Our previously published study reported that the cyclic-peptide SD01 exhibited specific binding to EphA2 (Ephrin type-A receptor 2) on TNBC. To develop a novel PET imaging agent, we prepared gallium-68 (68 Ga) labeled-DOTA-SD01 and evaluated its specificity and effectiveness through micro PET/CT imaging in a TNBC-bearing mouse model. SD01 and a control linear peptide YSA were conjugated to DOTA and subsequently labeled with 68 Ga, obtaining 68 Ga-DOTA-SD01 and 68 Ga-DOTA-YSA...
April 22, 2024: Dalton Transactions: An International Journal of Inorganic Chemistry
https://read.qxmd.com/read/38646672/inhibition-of-cdk7-mitigates-doxorubicin-cardiotoxicity-and-enhances-anticancer-efficacy
#16
JOURNAL ARTICLE
Jingrui Chen, Jing Wei, Peng Xia, Yuening Liu, Mahder Dawit Belew, Ryan Toohill, Boyang Jason Wu, Zhaokang Cheng
AIMS: The anthracycline family of anticancer agents such as doxorubicin (DOX) can induce apoptotic death of cardiomyocytes and cause cardiotoxicity. We previously reported that DOX-induced apoptosis is accompanied by cardiomyocyte cell cycle-reentry. Cell cycle progression requires cyclin-dependent kinase 7 (CDK7)-mediated activation of downstream cell cycle CDKs. This study aims to determine whether CDK7 can be targeted for cardioprotection during anthracycline chemotherapy. METHODS AND RESULTS: DOX exposure induced CDK7 activation in mouse heart and isolated cardiomyocytes...
April 22, 2024: Cardiovascular Research
https://read.qxmd.com/read/38646654/the-hsp90-inhibitor-hvh-2930-exhibits-potent-efficacy-against-trastuzumab-resistant-her2-positive-breast-cancer
#17
JOURNAL ARTICLE
Minsu Park, Eunsun Jung, Jung Min Park, Soeun Park, Dongmi Ko, Juyeon Seo, Seongjae Kim, Kee Dal Nam, Yong Koo Kang, Lee Farrand, Van-Hai Hoang, Cong-Truong Nguyen, Minh Thanh La, Gibeom Nam, Hyun-Ju Park, Jihyae Ann, Jeewoo Lee, Yoon-Jae Kim, Ji Young Kim, Jae Hong Seo
Rationale: Resistance to targeted therapies like trastuzumab remains a critical challenge for HER2-positive breast cancer patients. Despite the progress of several N-terminal HSP90 inhibitors in clinical trials, none have achieved approval for clinical use, primarily due to issues such as induction of the heat shock response (HSR), off-target effects, and unfavorable toxicity profiles. We sought to examine the effects of HVH-2930, a novel C-terminal HSP90 inhibitor, in overcoming trastuzumab resistance. Methods: The effect of HVH-2930 on trastuzumab-sensitive and -resistant cell lines in vitro was evaluated in terms of cell viability, expression of HSP90 client proteins, and impact on cancer stem cells...
2024: Theranostics
https://read.qxmd.com/read/38646527/the-functional-role-of-l-fucose-on-dendritic-cell-function-and-polarization
#18
JOURNAL ARTICLE
Chase Burton, Amirreza Bitaraf, Kara Snyder, Chaomei Zhang, Sean J Yoder, Dorina Avram, Dongliang Du, Xiaoqing Yu, Eric K Lau
Despite significant advances in the development and refinement of immunotherapies administered to combat cancer over the past decades, a number of barriers continue to limit their efficacy. One significant clinical barrier is the inability to mount initial immune responses towards the tumor. As dendritic cells are central initiators of immune responses in the body, the elucidation of mechanisms that can be therapeutically leveraged to enhance their functions to drive anti-tumor immune responses is urgently needed...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38646501/progress-in-cancer-research-on-the-regulator-of-phagocytosis-cd47-which-determines-the-fate-of-tumor-cells-review
#19
REVIEW
Fan Wu, Hongyuan Pang, Fan Li, Mengqing Hua, Chuanwang Song, Jie Tang
Cluster of differentiation 47 (CD47) is a transmembrane protein that is widely and moderately expressed on the surface of various cells and can have an essential role in mediating cell proliferation, migration, phagocytosis, apoptosis, immune homeostasis and other related responses by binding to its ligands, integrins, thrombospondin-1 and signal regulatory protein α. The poor prognosis of cancer patients is closely associated with high expression of CD47 in glioblastoma, ovarian cancer, breast cancer, bladder cancer, colon cancer and hepatocellular carcinoma...
June 2024: Oncology Letters
https://read.qxmd.com/read/38646498/metastatic-breast-cancer-with-double-heterozygosity-for-the-brca1-and-brca2-genes-responding-to-olaparib-a-case-report
#20
Bin Shao, Lijun Di
Olaparib was the first poly ADP-ribose polymerase inhibitor approved for patients with cancer with mutations in either BRCA1 or BRCA2 in China. To the best of our knowledge, however, no study has described the efficacy of olaparib for patients with breast cancer with double mutations in BRCA1 and BRCA2 . The present case report describes a patient with breast cancer with deleterious germline mutations in both BRCA1 and BRCA2 . The 56-year-old patient with multiple metastatic breast cancer underwent breast cancer resection with 12 years interval between removal of the left and right breast...
June 2024: Oncology Letters
keyword
keyword
55032
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.